OKY-1581: A selective inhibitor of thromboxane synthesis and |
| |
Authors: | Jean B. Smith William Jubiz |
| |
Affiliation: | 1. Veterans Administration Medical Center 84148, USA;2. University of Utah College of Medicine, Department of Medicine, Salt Lake City, Utah 84132, USA |
| |
Abstract: | OKY-1581 is an effective inhibitor of thromboxane synthesis and . The generation of thromboxane B2 (TxB2), prostaglandin E (PGE) and prostaglandin F (PGF) was measured following clotting and during platelet aggregation induced by collagen. The presence of OKY 1581 either or caused a reduction in TxB2 generation during clotting and platelet aggregation with a concomitant increase in PGE and PGF. The effect could be observed two hours after oral or subcutaneous administration of 5 to 100 mg per rabbit and lasted for 24 to 48 hours. The reduction in TxB2 was not accompanied by an inhibition of clotting or platelet aggregation. OKY-1581 appears to be a suitable agent for studying the role of TxB2 in atherosclerosis. |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|